Etazolate

Etazolate

Etazolate
Systematic (IUPAC) name
Ethyl 1-ethyl-4-[2-(propan-2-ylidene)hydrazinyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylate
Clinical data
Legal status
  • Uncontrolled
Routes of
administration
Oral
Identifiers
CAS Registry Number
ATC code None
PubChem CID:
IUPHAR/BPS
ChemSpider
UNII  YesY
ChEMBL
Chemical data
Formula C14H19N5O2
Molecular mass 289.33 g/mol

Etazolate (SQ-20,009, EHT-0202) is an anxiolytic drug which is a pyrazolopyridine derivative and has unique pharmacological properties.[1][2][3] It acts as a positive allosteric modulator of the GABAA receptor at the barbiturate binding site,[4][5][6][7] as an adenosine antagonist of the A1 and A2 subtypes,[8] and as a phosphodiesterase inhibitor selective for the PDE4 isoform.[9][10][11] It is currently in clinical trials for the treatment of Alzheimer's disease.[12]

Synthesis

Cartazolate and Etazolate synthesis: E.R. SQUIBB & SONS, INC., NEW YORK, N.Y., US. DE 2123318 

See also

References

  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^
  10. ^
  11. ^
  12. ^